Original language | English (US) |
---|---|
Pages (from-to) | 2974-2978 |
Number of pages | 5 |
Journal | Leukemia |
Volume | 33 |
Issue number | 12 |
DOIs | |
State | Published - Dec 1 2019 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. / Mascarenhas, J.; Kosiorek, H.; Prchal, J. et al.
In: Leukemia, Vol. 33, No. 12, 01.12.2019, p. 2974-2978.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
AU - Mascarenhas, J.
AU - Kosiorek, H.
AU - Prchal, J.
AU - Yacoub, A.
AU - Berenzon, D.
AU - Baer, M. R.
AU - Ritchie, E.
AU - Silver, R. T.
AU - Kessler, C.
AU - Winton, E.
AU - Finazzi, M. C.
AU - Rambaldi, A.
AU - Vannucchi, A. M.
AU - Leibowitz, D.
AU - Rondelli, D.
AU - Arcasoy, M. O.
AU - Catchatourian, R.
AU - Vadakara, J.
AU - Rosti, V.
AU - Hexner, E.
AU - Kremyanskaya, M.
AU - Sandy, L.
AU - Tripodi, J.
AU - Najfeld, V.
AU - Farnoud, N.
AU - Salama, M. E.
AU - Weinberg, R. S.
AU - Rampal, R.
AU - Goldberg, J. D.
AU - Mesa, R.
AU - Dueck, A. C.
AU - Hoffman, R.
N1 - Funding Information: Conflict of interest J.M. reports clinical trial research support paid to the institution from Incyte, Roche, Novartis, CTI Biopharma, Janssen, Merck, Promedior, and Celgene; clinical trial steering committee and scientific advisory board member: Roche, CTI Biopharma, Incyte, and Celgene. M.R.B. reports clinical trial research support paid to the institution from Abbvie, AI, Astellas, Forma, Incyte, Kite, and Takeda. M.A. reports research grant support paid to institution from Incyte, CTI Biopharma, Samus Therapeutics, Janssen, and Gilead. R.T.S. Funding Information: Acknowledgements This research was made possible by a grant from the National Cancer Institute of the National Institute of Health (MPN Research Consortium Grant, 5P01CA108671–09) and generous independent, unrestricted support from Roche Genentech.
PY - 2019/12/1
Y1 - 2019/12/1
UR - http://www.scopus.com/inward/record.url?scp=85069946674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069946674&partnerID=8YFLogxK
U2 - 10.1038/s41375-019-0524-7
DO - 10.1038/s41375-019-0524-7
M3 - Letter
C2 - 31363161
AN - SCOPUS:85069946674
VL - 33
SP - 2974
EP - 2978
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 12
ER -